Sphingotec – bio-ADM® for ICU


Sphingotec – bio-ADM® – Explainer video

Sphingotec is a German biotech company developing biomarkers for testing patients in the ICU (Intensive Care Unit) for acute medical conditions such as organ failure (kidney failure, heart failure), sepsis, and other, often fatal conditions.

bio-ADM® animation is the first of the series of 3 videos presenting their proprietary markers and how their advantages over the current testing procedures.

bio-ADM® is a biomarker of endothelial function.



This video represents a classical medical-style animation. The main focus of the video is the action happening inside the blood vessels and around the endothelial cells, where typically organ failure and septic shock originate from.



In critical care settings, one of the main causes of organ failure and ultimately mortality is loss of endothelial function, which is associated with leakage of blood vessels.

Although the symptoms of loss of endothelial functions are well-known, there are currently no simple, blood-based detection methods established for monitoring the worsening and improvement of endothelial function.

Research has identified bioactive Adrenomedullin (bio-ADM®) as a controlling hormone of the endothelial barrier – the interior wall protecting the blood vessels. In certain conditions such as septic shock, cardiogenic shock or acute heart failure, the endothelial barrier becomes leaky, and additional bioactive Adrenomedullin is produced to re-seal the barrier. However,  bio-ADM® has a second function. It also expands the blood vessels, resulting in a dangerous blood pressure drop, which leads to shock and may ultimately escalate into multiple organ failure.

bio-ADM® can easily be measured in the blood, enabling the assessment of the endothelial barrier up to 48 hours before the symptoms become visible. Regular assessment of the bio-ADM® levels allows for the monitoring of critically ill patients. Elevated bio-ADM blood levels predict both blood pressure drop resulting in shock as well as leaky vessels leading to the formation of edema. Decreasing levels of bio-ADM® reflect an improvement of the endothelial function, which is closely associated with the patient’s clinical condition. 

Using the sphingotec bio-ADM® assay, clinicians can now monitor levels of bio-ADM® to identify treatment responders and non-responders in order to improve patient management, including discharge decisions. 


If you want to know more, please check the customer’s website.

See more of our medical animations here.